FY2025 Earnings Estimate for BDX Issued By Zacks Research

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a research note issued to investors on Thursday, April 10th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $14.40 per share for the year, down from their previous forecast of $14.43. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q3 2026 earnings at $4.05 EPS, Q4 2026 earnings at $4.52 EPS, FY2026 earnings at $15.55 EPS, Q2 2027 earnings at $4.14 EPS and FY2027 earnings at $16.79 EPS.

Several other research firms have also commented on BDX. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating for the company in a research note on Monday, April 7th. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $275.71.

Becton, Dickinson and Company Stock Up 1.9 %

BDX opened at $205.65 on Monday. Becton, Dickinson and Company has a fifty-two week low of $193.03 and a fifty-two week high of $251.99. The firm has a market capitalization of $59.05 billion, a P/E ratio of 34.16, a PEG ratio of 1.63 and a beta of 0.35. The company’s 50-day moving average is $223.18 and its 200 day moving average is $229.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were paid a $1.04 dividend. The ex-dividend date was Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 2.02%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total transaction of $159,593.00. Following the sale, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson acquired 1,500 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was acquired at an average cost of $233.62 per share, with a total value of $350,430.00. Following the completion of the acquisition, the director now owns 8,015 shares in the company, valued at $1,872,464.30. This trade represents a 23.02 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 4,675 shares of company stock valued at $1,057,182. Company insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors have recently made changes to their positions in the stock. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $25,000. Sierra Ocean LLC purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. REAP Financial Group LLC increased its position in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 55 shares during the period. Picton Mahoney Asset Management lifted its holdings in shares of Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new position in shares of Becton, Dickinson and Company in the first quarter valued at approximately $34,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.